A New-Generation ALK Inhibitor in Lung Cancer: Neladalkib Targets Resistant Cells
In this article
Strong Signals with Neladalkib in Brain Metastases and Resistance After Lorlatinib
The Main Challenge in ALK-Positive Disease Is Now Resistance and Brain Control, Not the Initial Response
In ALK-positive NSCLC, first-line ALK inhibitors can achieve high response rates and long progression-free survival. However, the disease often develops resistance over time. Resistance mechanisms include ALK kinase domain mutations, compound resistance mutations, bypass signaling pathways and central nervous system progression.
Brain metastases are a particularly critical problem in ALK-positive lung cancer. Central nervous system involvement is frequent, and a drug's ability to penetrate the brain is decisive in treatment selection. Although third-generation ALK inhibitors such as lorlatinib have brought substantial progress in this area, options remain limited for patients whose disease progresses after lorlatinib.
Brief Concept Note: What Are ALK-Positive NSCLC and an ALK TKI?
ALK-positive NSCLCis a specific molecular subgroup of lung cancer arising from fusion of the ALK gene with another gene. This fusion sends the cancer cell a continuous growth signal. ALK TKIstands for ALK tyrosine kinase inhibitor, a group of targeted drugs that suppress this abnormal growth signal.
Why Was Neladalkib Designed Differently?
Neladalkib is an investigational oral, brain-penetrant, ALK-selective inhibitor. One of its design goals is activity against resistance mutations that can arise after first-, second- and third-generation ALK inhibitors.
Another important feature is its TRK-sparing design. Some ALK inhibitors also suppress TRK family kinases, which can be associated with neurological side effects. Designing neladalkib to avoid TRK inhibition may provide a theoretical tolerability advantage for a strongly brain-penetrant ALK inhibitor.
Brief Concept Note: What Does TRK-Sparing Mean?
TRK-sparingmeans selectively inhibiting ALK while avoiding, as far as possible, suppression of structurally similar kinases called TRK. The aim is to maintain the antitumor effect on ALK while reducing some neurological side effects that might be related to TRK inhibition.
Global First-in-Human Phase 1/2 Study
ALKOVE-1 is a global, open-label, first-in-human phase 1/2 study in advanced ALK-positive NSCLC and other ALK-positive solid tumors. Dose escalation from 15–200 mg was performed in phase 1; the recommended dose for phase 2 was established as 150 mg, 1 time daily for treatment.
The primary endpoint of phase 2 was objective response rate according to independent central review. Duration of response, progression-free survival, overall survival, intracranial activity, overall safety and pharmacokinetics were assessed as important additional endpoints.
| Aspect | Detail | Clinical meaning |
|---|---|---|
| Study type | Global, open-label, phase 1/2, first-in-human study | Both dose/safety and signals of efficacy were investigated. |
| Drug | Neladalkib, an oral, ALK-selective, brain-penetrant TKI | A new-generation approach targeting resistance and CNS disease. |
| Recommended phase 2 dose | 150 mg, 1 time daily | ASCO 2026 data are interpreted at this dose. |
| Phase 2 primary endpoint | Objective response rate assessed by BICR | Measures tumor shrinkage through independent central review. |
| Important additional endpoints | DOR, PFS, OS, intracranial activity and safety | Depth and duration of response, brain control and tolerability are assessed together. |
Brief Concept Note: What Are BICR, ORR and DOR?
BICRstands for blinded independent central review: imaging is centrally assessed by independent experts who do not know the treatment arm. ORRis the objective response rate: the proportion of patients whose tumors shrink measurably. DORis duration of response: how long the response lasts.
A Truly Resistant and Heavily Treated Population
The TKI-pretreated efficacy population included 253 patients . This group represents one of the most challenging populations in advanced ALK-positive NSCLC practice. %51 had previously received chemotherapy, %95 a second-generation ALK TKI and %75 lorlatinib. The proportion with brain metastases at baseline was %40.
The population was challenging in terms of molecular resistance as well. %36 had a secondary ALK mutation, %19 an ALK G1202R mutation and %17 two or more ALK mutations. These details show that neladalkib was tested not merely in easy responders, but in a population with established resistance biology.
Brief Concept Note: Why Do Lorlatinib and G1202R Matter?
Lorlatinibis a third-generation, strongly brain-penetrant ALK inhibitor and one of the highly effective options in ALK-positive NSCLC. However, treatment options become limited when the disease progresses after lorlatinib. ALK G1202Ris an important ALK mutation particularly associated with resistance to second-generation ALK inhibitors. It may occur alone or together with other mutations.
ORR %31 in Pretreated Patients; %46 in the Lorlatinib-Naive Group
In 253 TKI-pretreated patients, the objective response rate with neladalkib was %31 as reported. This is clinically meaningful considering that the overall group was substantially pretreated and resistant.
Response rates varied by subgroup. In lorlatinib-naive patients, ORR was %46 , while in lorlatinib-experienced patients it was %26 . In patients pretreated only with alectinib, ORR was %48, and in those who had received two or more previous ALK TKIs it was %28 according to the reported results.
Duration of Response: A More Durable Signal in Lorlatinib-Naive Patients
Among all responding TKI-pretreated patients, %64 of responses lasted 12 months or longer . In the lorlatinib-naive group, this rate was %80 . In the lorlatinib-experienced group, the proportion of responses lasting 12 months or longer was %54, and median duration of response was 17,6 months as reported.
CNS Efficacy Is One of Neladalkib's Most Critical Areas of Differentiation
Brain metastases are common in ALK-positive lung cancer, making intracranial efficacy decisive in treatment selection. In ALKOVE-1, intracranial ORR among 92 TKI-pretreated patients evaluable for CNS response was %32 . In lorlatinib-naive patients this rate was %63, and in lorlatinib-experienced patients it was %21 as reported.
Brief Concept Note: What Are Intracranial ORR and CNS Penetration?
Intracranial ORRis the proportion of measurable brain metastases that shrink with treatment. CNS penetrationdescribes how well a drug reaches the central nervous system, meaning the brain and cerebrospinal fluid compartment. This property is very important in ALK-positive patients with brain metastases.
| Patient group | Number of CNS-evaluable patients | Intracranial ORR | Intracranial CR | IC-DOR of 12 months or longer | Clinical interpretation |
|---|---|---|---|---|---|
| All TKI-pretreated patients | 92 | %32 | %13 | %71 | Meaningful CNS activity in a pretreated, resistant population. |
| Lorlatinib-naive | 24 | %63 | %21 | %92 | A very strong intracranial response signal in patients who had not received lorlatinib. |
| Lorlatinib-experienced | 68 | %21 | %10 | %55 | Measurable CNS activity is observed even after lorlatinib. |
Strong Response Signal in ALK G1202R
ALK G1202R is one of the most important resistance mutations in ALK-positive NSCLC. ALKOVE-1 summary slides reported strong activity of neladalkib in patients with single or compound G1202R resistance mutations. ORR in lorlatinib-naive G1202R patients was %83, and in lorlatinib-experienced G1202R patients it was %63 as reported. The proportions with response duration of 12 months or longer were, respectively, %77 and %81 in the reported results.
Why Do These Findings Matter?
- G1202R is a challenging resistance mechanism: Activity against this mutation suggests that the drug could be valuable in strategies after resistance develops.
- Activity after lorlatinib is critical: Options are limited for lorlatinib-experienced patients, making the %63 ORR signal noteworthy.
- Durability of responses matters: High rates of DOR lasting 12 months or longer suggest not merely rapid response but also the potential for lasting control.
An Early First-Line Signal: ORR %86, CNS ORR %78
Preliminary data were reported for 44 response-evaluable patients in ALKOVE-1's exploratory treatment-naive cohort. In this small group, the objective response rate was %86 ; the complete response rate was %9 as reported. An estimated %91 of responses lasted 12 months or longer in this cohort.
In 9 patients evaluable for CNS response, intracranial ORR was %78, and the intracranial complete response rate was %44 . No CNS progression events were reported among intracranial responders. These data remain early and are based on a small number of patients, but strongly support investigating neladalkib in the first-line setting.
Truecheck Note: Treatment-Naive Data Are Early and Based on Small Numbers
The %86 ORR and %78 CNS ORR in the TKI-naive group appear very strong. However, these data are based on only 44 patients evaluable for systemic response and 9 evaluable for CNS response. Randomized phase 3 confirmation is therefore needed before changing the first-line standard.
Low Treatment Discontinuation Rate: Could This Be a Clinical Benefit of the TRK-Sparing Design?
Neladalkib showed a generally well-tolerated safety profile. In advanced ALK-positive NSCLC patients treated at RP2D in ALKOVE-1, the rate of dose reduction due to side effects was %17, and the treatment discontinuation rate was %5 as reported. This low discontinuation rate is clinically important, particularly for chronic targeted therapies.
The most commonly reported side effects included elevated ALT, elevated AST, constipation, altered taste, peripheral edema, cough and nausea. Transaminase elevations were mostly described as asymptomatic laboratory abnormalities and appeared manageable through dose interruptions or reductions.
Brief Concept Note: What Does a Transaminase Increase Mean?
ALT and ASTare enzymes released by liver cells. An increase may indicate that the drug is affecting the liver. Not every elevation means serious liver damage, but regular blood test monitoring, dose interruptions or dose reductions may be necessary.
| Safety aspect | Rate/finding | Clinical interpretation |
|---|---|---|
| Dose reduction | %17 | Dose reductions due to side effects were reported at a relatively low rate. |
| Treatment discontinuation | %5 | A positive tolerability signal for chronic ALK therapy. |
| ALT elevation | %47 | One of the most frequent laboratory side effects; liver tests should be monitored. |
| AST elevation | %44 | Most were described as low-grade and manageable. |
| TRK-sparing design | A distinctive feature of the drug's design | May have the potential to reduce TRK-related neurological side effects; clinical confirmation is important. |
Why Does ALK Treatment Continually Need New Generations of Drugs?
Crizotinib brought the first major breakthrough in ALK-positive NSCLC treatment. Second-generation ALK inhibitors such as alectinib, brigatinib and ensartinib then improved both systemic efficacy and brain control. Lorlatinib, a third-generation, strongly brain-penetrant ALK inhibitor, became an important option particularly for resistance mutations and CNS disease.
However, each generation produced a new wave of resistance. Compound ALK mutations arising after lorlatinib, G1202R and other resistance mechanisms increased the need for new-generation, more selective ALK inhibitors. Neladalkib should be understood as a drug arising from this need: a next-step candidate that penetrates the brain, is selective for ALK, spares TRK and is designed against resistance mutations.
| Era | Main drugs | Strength | Limitation | Relationship to neladalkib |
|---|---|---|---|---|
| 1st-generation ALK TKI | Crizotinib | Launched the era of ALK-targeted treatment | Limitations in CNS control and resistance | Created a need for more potent, brain-penetrant drugs. |
| 2nd-generation ALK TKI | Alectinib, brigatinib, ceritinib, ensartinib | Better systemic and CNS control | Resistance mutations and the need for subsequent treatment | Mutations such as G1202R became targets for new drugs. |
| 3rd-generation ALK TKI | Lorlatinib | Strong CNS activity and broad activity against resistance mutations | Options after lorlatinib are limited; neurocognitive/metabolic side effects remain debated | Neladalkib is becoming especially important in resistance after lorlatinib. |
| New-generation selective approach | Neladalkib | ALK-selective, TRK-sparing, brain-penetrant design directed against resistance mutations | Still investigational; phase 3 confirmation is needed | A candidate for a new treatment algorithm both after TKIs and in the first line. |
The Main First-Line Question: Can Neladalkib Outperform Alectinib?
Although ALKOVE-1's preliminary treatment-naive data are very promising, a randomized comparison is needed to change the first-line standard. Therefore, the ongoing ALKAZAR phase 3 study is critically important. ALKAZAR is a global randomized study designed to compare neladalkib with alectinib in TKI-naive patients with ALK-positive NSCLC.
The study's primary endpoint is progression-free survival assessed by BICR. If ALKAZAR shows that neladalkib provides meaningful PFS and CNS advantages over alectinib with manageable safety, first-line treatment sequencing in ALK-positive NSCLC could be reshaped.
Truecheck Note
Neladalkib is still an investigational drug and has not been approved by the FDA or any other health authority. Although ALKOVE-1 data provide strong signals of efficacy and safety, randomized phase 3 results and regulatory assessments must be awaited to determine the treatment's place in standard practice.
A New Candidate After Lorlatinib and in CNS Disease
The strongest current clinical message from ALKOVE-1 is that neladalkib shows meaningful activity particularly in ALK TKI-pretreated patients with limited options. Systemic and intracranial responses even in lorlatinib-experienced patients increase the drug's potential value in treatment after resistance develops.
CNS activity is also particularly important. A substantial proportion of patients with ALK-positive NSCLC develop brain metastases at some point during their disease. A new ALK inhibitor demonstrating not only systemic but also intracranial response therefore has a strong advantage in the clinical treatment algorithm.
Clinical Lessons That Can Be Drawn Today
- Testing for ALK resistance mutations is gaining importance: G1202R and compound ALK mutations may become increasingly decisive in treatment sequencing.
- CNS efficacy is critical: Drug selection in patients with brain metastases should not be based solely on systemic ORR.
- The gap after lorlatinib remains: Neladalkib is a strong candidate in this area, but approval and phase 3 data must be awaited.
- There is first-line potential: TKI-naive ORR %86 and CNS ORR %78 make the ALKAZAR study very important.
- Long-term tolerability will be decisive: ALK-positive patients may remain on treatment for years, making a low discontinuation rate valuable.
How Should This Be Discussed with a Patient?
“There are many effective targeted drugs for ALK-positive lung cancer, but resistance can develop over time, and brain metastases can become particularly important. Although still investigational, a new drug called neladalkib has shown promising responses in patients previously treated with ALK drugs and in those with brain metastases. It is not yet a standard treatment, but it could become an important future option, particularly after resistance and for brain control.”
A New Goal in ALK Treatment: Controlling the Brain and Mutations Together After Resistance
Academic Assessment
Neladalkib data are important because they offer new treatment hope in difficult clinical situations in ALK-positive lung cancer, particularly resistance after lorlatinib, brain metastases and mutations such as G1202R.
Durability of responses, intracranial activity and a low treatment discontinuation rate make this drug not just another ALK inhibitor but a strong candidate for strategies after resistance develops.
Future ALK treatment will be planned more precisely according not only to which drug is more effective but also to brain protection, resistance mutation profiles and treatment sequencing.
Which Data Will Determine Neladalkib's True Place?
Open Questions
- ALKAZAR results: Will neladalkib be superior to alectinib for PFS and CNS control in the first line?
- Resistance after lorlatinib: Which resistance mutations show the strongest activity?
- G1202R and compound mutations: Will responses show the same durability in real-world practice?
- Long-term CNS control: How durable will responses in brain metastases be?
- TRK-sparing advantage: Will it make a clinically meaningful difference in neurological tolerability?
- Treatment sequencing: In what sequence do alectinib, brigatinib, lorlatinib and neladalkib provide the best results?
Neladalkib: A Strong Candidate for the Era of Resistance and Brain Metastases in ALK-Positive Lung Cancer
ALKOVE-1 data presented at ASCO 2026 show that neladalkib can provide meaningful clinical activity in advanced ALK-positive NSCLC, particularly in patients pretreated with ALK TKIs, experienced with lorlatinib, with brain metastases or with resistance mutations such as ALK G1202R. ORR was %31 among all TKI-pretreated patients, %46 in the lorlatinib-naive group and %26 in the lorlatinib-experienced group. A substantial proportion of responses continued for 12 months or longer.
The drug's intracranial activity is also noteworthy. Intracranial ORR was reported as %32 in TKI-pretreated CNS-response-evaluable patients, %63 in the lorlatinib-naive group and %21 in the lorlatinib-experienced group. Strong early results of systemic ORR %86 and intracranial ORR %78 were obtained in the small preliminary TKI-naive cohort.
These findings make neladalkib a candidate to watch closely both after resistance and in first-line ALK-positive NSCLC. However, a final decision to change today's standard will depend on results of randomized phase 3 studies such as ALKAZAR and regulatory assessments. The future of ALK treatment will be shaped not only by stronger ALK inhibition but also by smarter treatment sequencing that simultaneously optimizes brain protection, resistance mutation management and long-term tolerability.
Sources
- ASCO 2026 Abstract 8503. ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
- Nuvalent. Neladalkib ALKOVE-1 data presentation at ASCO 2026. 21 April 2026.
- Nuvalent. Positive topline pivotal data from ALKOVE-1 trial of neladalkib. 17 November 2025.
- ClinicalTrials.gov. ALKOVE-1: A Study of Neladalkib in ALK-positive NSCLC and other solid tumors. NCT05384626.
- ClinicalTrials.gov. ALKAZAR: Neladalkib versus alectinib in TKI-naive ALK-positive NSCLC. NCT06765109.
- OncLive. FDA Grants Priority Review to Neladalkib for TKI-Pretreated ALK+ NSCLC. 2026.
- OncLive. NDA Is Submitted to FDA for Neladalkib in TKI-Pretreated Advanced ALK+ NSCLC. 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.